Clinical Trial Update: CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CART123 CAR-T cells with or without the JAK2 inhibitor ruxolitinib in relapsed/refractory acute myeloid leukemia; the study status is N…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CART123
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Stephan Grupp MD PhD | Conditions: Acute Myeloid Leukemia (AML) | Phase 1 | Status: NOT_YET_RECRUITING